Therapeutic dose heparin

Therapeutic heparin use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 15.6, 95% CI 1.88-129, p=0.006).

Effect: adverse; OR 15.6; CI: 95% CI 1.88 to 129

Therapeutic heparin use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 15.6, 95% CI 1.88-129, p=0.006).

Effect: adverse; OR 15.6; CI: 95% CI 1.88 to 129

Therapeutic heparin use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 15.6, 95% CI 1.88-129, p=0.006).

Effect: adverse; OR 15.6; CI: 95% CI 1.88 to 129

Therapeutic heparin use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 15.6, 95% CI 1.88-129, p=0.006).

Effect: adverse; OR 15.6; CI: 95% CI 1.88 to 129

Therapeutic heparin use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 15.6, 95% CI 1.88-129, p=0.006).

Effect: adverse; OR 15.6; CI: 95% CI 1.88 to 129

Therapeutic heparin use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 15.6, 95% CI 1.88-129, p=0.006).

Effect: adverse; OR 15.6; CI: 95% CI 1.88 to 129

Therapeutic heparin use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 15.6, 95% CI 1.88-129, p=0.006).

Effect: adverse; OR 15.6; CI: 95% CI 1.88 to 129

Therapeutic heparin use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 15.6, 95% CI 1.88-129, p=0.006).

Effect: adverse; OR 15.6; CI: 95% CI 1.88 to 129

Therapeutic heparin use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 15.6, 95% CI 1.88-129, p=0.006).

Effect: adverse; OR 15.6; CI: 95% CI 1.88 to 129

Therapeutic heparin use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 15.6, 95% CI 1.88-129, p=0.006).

Effect: adverse; OR 15.6; CI: 95% CI 1.88 to 129

Therapeutic heparin use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 15.6, 95% CI 1.88-129, p=0.006).

Effect: adverse; OR 15.6; CI: 95% CI 1.88 to 129

Therapeutic heparin use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 15.6, 95% CI 1.88-129, p=0.006).

Effect: adverse; OR 15.6; CI: 95% CI 1.88 to 129

Therapeutic heparin use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 15.6, 95% CI 1.88-129, p=0.006).

Effect: adverse; OR 15.6; CI: 95% CI 1.88 to 129

Therapeutic heparin use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 15.6, 95% CI 1.88-129, p=0.006).

Effect: adverse; OR 15.6; CI: 95% CI 1.88 to 129

Therapeutic heparin use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 15.6, 95% CI 1.88-129, p=0.006).

Effect: adverse; OR 15.6; CI: 95% CI 1.88 to 129

Therapeutic heparin use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 15.6, 95% CI 1.88-129, p=0.006).

Effect: adverse; OR 15.6; CI: 95% CI 1.88 to 129

Therapeutic heparin use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 15.6, 95% CI 1.88-129, p=0.006).

Effect: adverse; OR 15.6; CI: 95% CI 1.88 to 129

Therapeutic heparin use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 15.6, 95% CI 1.88-129, p=0.006).

Effect: adverse; OR 15.6; CI: 95% CI 1.88 to 129

Therapeutic heparin use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 15.6, 95% CI 1.88-129, p=0.006).

Effect: adverse; OR 15.6; CI: 95% CI 1.88 to 129

Therapeutic heparin use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 15.6, 95% CI 1.88-129, p=0.006).

Effect: adverse; OR 15.6; CI: 95% CI 1.88 to 129

Therapeutic heparin use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 15.6, 95% CI 1.88-129, p=0.006).

Effect: adverse; OR 15.6; CI: 95% CI 1.88 to 129

Therapeutic heparin use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 15.6, 95% CI 1.88-129, p=0.006).

Effect: adverse; OR 15.6; CI: 95% CI 1.88 to 129

Therapeutic heparin use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 15.6, 95% CI 1.88-129, p=0.006).

Effect: adverse; OR 15.6; CI: 95% CI 1.88 to 129

Therapeutic heparin use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 15.6, 95% CI 1.88-129, p=0.006).

Effect: adverse; OR 15.6; CI: 95% CI 1.88 to 129

Therapeutic heparin use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 15.6, 95% CI 1.88-129, p=0.006).

Effect: adverse; OR 15.6; CI: 95% CI 1.88 to 129

Therapeutic heparin use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 15.6, 95% CI 1.88-129, p=0.006).

Effect: adverse; OR 15.6; CI: 95% CI 1.88 to 129

Therapeutic heparin use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 15.6, 95% CI 1.88-129, p=0.006).

Effect: adverse; OR 15.6; CI: 95% CI 1.88 to 129